# RP11-Derived Long Non-Coding RNAs in Hepatocellular Carcinoma: Hidden Treasures in Plain Sight

## TL;DR

This paper reviews the emerging role of RP11-derived long non-coding RNAs in liver cancer, highlighting their potential as biomarkers and therapeutic targets.

## Contribution

The paper systematically compiles recent findings on RP11-derived lncRNAs in hepatocellular carcinoma, emphasizing their functional and clinical relevance.

## Key findings

- RP11-derived lncRNAs influence metabolic reprogramming and tumor progression in HCC.
- These lncRNAs modulate microRNA networks and show diagnostic/prognostic value in HCC.
- Potential therapeutic opportunities exist for translating RP11-derived lncRNAs into clinical applications.

## Abstract

Hepatocellular carcinoma (HCC) remains one of the most prevalent and lethal malignancies worldwide. Long non-coding RNAs (lncRNAs) have emerged as crucial regulators of gene expression and cancer progression, yet the functional diversity of RP11-derived lncRNAs—originally mapped to bacterial artificial chromosome (BAC) clones from the Roswell Park Cancer Institute—has only recently begun to be appreciated. This mini-review aims to systematically synthesize current findings on RP11-derived lncRNAs in HCC, outlining their genomic origins, molecular mechanisms, and biological significance. We highlight their roles in metabolic reprogramming, microRNA network modulation, and tumor progression, as well as their diagnostic and prognostic value in tissue and serum-based analyses. Finally, we discuss therapeutic opportunities and propose future directions to translate RP11-derived lncRNAs into clinically actionable biomarkers and targets for precision liver cancer therapy.